A Phase I, Open-label Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]RIST4721 Following a Single Oral Dose to Healthy Male Subjects
Latest Information Update: 12 Jan 2022
At a glance
- Drugs RIST 4721 (Primary)
- Indications Palmoplantar pustulosis
- Focus Pharmacokinetics
- Sponsors Aristea Therapeutics
- 06 Jan 2022 Status changed from recruiting to completed.
- 01 Sep 2021 New trial record